**Supplemental Table 1: Classification of indications for antifungal use for data analysis**

|  |  |  |
| --- | --- | --- |
| **Indications on data collection forms** | | **Study classification** |
| **Indication for treatment** | **Empiric vs targeted** |
| Prophylaxis | N/A | Prophylaxis |
| Other indications:   * Community acquired infection * Healthcare-associated infection | * Empiric without culture(s) performed * Empiric but culture and susceptibility testing pending * Empiric without positive cultures | Empiric |
| * Empiric and pathogen identified * Targeted and pathogen and antimicrobial resistance confirmed | Targeted |
| Unknown | N/A | Unknown |

N/A: not applicable

**Supplemental Table 2: Azole antifungals by route of administration**

|  |  |  |  |
| --- | --- | --- | --- |
| **Azole antifungal** | **Parenteral,**  **(N=624)**  **No.** | **Enteral,**  **(N=864)**  **No.** | **Unknown,**  **(N=5)**  **No.** |
| Fluconazole | 513 | 535 | 3 |
| Voriconazole | 86 | 241 | 2 |
| Posaconazole | 24 | 68 | - |
| Itraconazole | - | 19 | - |
| Isavuconazole | 1 | - | - |
| Ketoconazole | - | 1 | - |